Amarin Corporation (AMRN)
0.59
-0.00 (-0.19%)
At close: Feb 20, 2025, 3:59 PM
0.59
-0.15%
After-hours: Feb 20, 2025, 05:54 PM EST
undefined% (undefined)
| Bid | 0.59 |
| Market Cap | 243.06M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.1 |
| PE Ratio (ttm) | -5.91 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.59 |
| Volume | 559,344 |
| Avg. Volume (20D) | 1,470,979 |
| Open | 0.59 |
| Previous Close | 0.59 |
| Day's Range | 0.56 - 0.61 |
| 52-Week Range | 0.43 - 1.36 |
| Beta | undefined |
About AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its p...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 1, 1993
Employees 275
Stock Exchange NASDAQ
Ticker Symbol AMRN
Website https://www.amarincorp.com
Analyst Forecast
According to 2 analyst ratings, the average rating for AMRN stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 50.00%
Hold 0.00%
Sell 50.00%
Next Earnings Release
Amarin Corporation is scheduled to release its earnings on Mar 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
-12.87%
Amarin shares are trading lower. The company repor...
Unlock content with
Pro Subscription
7 months ago
-1.28%
Amarin shares are trading higher after the company received national reimbursement for VAZKEPA in Portugal.
